Hypothalamic-pituitary and other endocrine surveillance among childhood cancer survivors.
Author
van Iersel, LauraMulder, Renee L
Denzer, Christian
Cohen, Laurie E
Spoudeas, Helen A
Meacham, Lillian R
Sugden, Elaine
Schouten-van Meeteren, Antoinette Y N
Hoving, Eelco W
Packer, Roger J
Armstrong, Gregory T
Mostoufi-Moab, Sogol
Stades, Aline M
van Vuurden, Dannis
Janssens, Geert O
Thomas-Teinturier, Cécile
Murray, Robert D
Di Iorgi, Natascia
Neggers, Sebastian J C M M
Thompson, Joel
Toogood, Andrew A
Gleeson, Helena
Follin, Cecilia
Bardi, Edit
Torno, Lilibeth
Patterson, Briana
Morsellino, Vera
Sommer, Grit
Clement, Sarah C
Srivastava, Deokumar
Kiserud, Cecilie E
Fernandez, Alberto
Scheinemann, Katrin
Raman, Sripriya
Yuen, Kevin C J
Wallace, W Hamish
Constine, Louis S
Skinner, Roderick
Hudson, Melissa M
Kremer, Leontien C M
Chemaitilly, Wassim
van Santen, Hanneke M
Publication date
2022-09-26
Metadata
Show full item recordAbstract
ndocrine disorders in survivors of childhood, adolescent, and young adult (CAYA) cancers are associated with substantial adverse physical and psychosocial effects. To improve appropriate and timely endocrine screening and referral to a specialist, the International Late Effects of Childhood Cancer Guideline Harmonization Group (IGHG) aims to develop evidence and expert consensus-based guidelines for healthcare providers that harmonize recommendations for surveillance of endocrine disorders in CAYA cancer survivors. Existing IGHG surveillance recommendations for premature ovarian insufficiency, gonadotoxicity in males, fertility preservation, and thyroid cancer are summarized. For hypothalamic-pituitary (HP) dysfunction, new surveillance recommendations were formulated by a guideline panel consisting of 42 interdisciplinary international experts. A systematic literature search was performed in MEDLINE (through PubMed) for clinically relevant questions concerning HP dysfunction. Literature was screened for eligibility. Recommendations were formulated by drawing conclusions from quality assessment of all evidence, considering the potential benefits of early detection and appropriate management. Healthcare providers should be aware that CAYA cancer survivors have an increased risk for endocrine disorders, including HP dysfunction. Regular surveillance with clinical history, anthropomorphic measures, physical examination, and laboratory measurements is recommended in at-risk survivors. When endocrine disorders are suspected, healthcare providers should proceed with timely referrals to specialized services. These international evidence-based recommendations for surveillance of endocrine disorders in CAYA cancer survivors inform healthcare providers and highlight the need for long-term endocrine follow-up care in subgroups of survivors and elucidate opportunities for further research.Citation
van Iersel L, Mulder RL, Denzer C, Cohen LE, Spoudeas HA, Meacham LR, Sugden E, Schouten-van Meeteren AYN, Hoving EW, Packer RJ, Armstrong GT, Mostoufi-Moab S, Stades AM, van Vuurden D, Janssens GO, Thomas-Teinturier C, Murray RD, Di Iorgi N, Neggers SJCMM, Thompson J, Toogood AA, Gleeson H, Follin C, Bardi E, Torno L, Patterson B, Morsellino V, Sommer G, Clement SC, Srivastava D, Kiserud CE, Fernandez A, Scheinemann K, Raman S, Yuen KCJ, Wallace WH, Constine LS, Skinner R, Hudson MM, Kremer LCM, Chemaitilly W, van Santen HM. Hypothalamic-Pituitary and Other Endocrine Surveillance Among Childhood Cancer Survivors. Endocr Rev. 2022 Sep 26;43(5):794-823. doi: 10.1210/endrev/bnab040Type
ArticleAdditional Links
https://academic.oup.com/edrvPMID
34962573Journal
Endocrine ReviewsPublisher
Oxford University Pressae974a485f413a2113503eed53cd6c53
10.1210/endrev/bnab040